英夫利昔单抗-abda
Infliximab-abda
作者信息
Aboobacker Shamma, Patel Preeti, Al Aboud Ahmad M.
机构信息
Al Arif Heart & Children Medical Centre
King Abdullah Medical City
Infliximab-abda is a biosimilar monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α), a cytokine involved in inflammatory and autoimmune pathophysiology. This activity presents a focused review of infliximab-abda's mechanism of action, therapeutic indications across dermatology, immunology, gastroenterology, and rheumatology, and relevant contraindications. Particular attention is given to the historical context of anti-TNF-α therapy, beginning with FDA approval in 1998 and subsequent dermatologic use in 2002.
英夫利昔单抗-abda是一种生物类似单克隆抗体，靶向肿瘤坏死因子-α（TNF-α），TNF-α是一种参与炎症和自身免疫病理生理过程的细胞因子。本文聚焦综述英夫利昔单抗-abda的作用机制、在皮肤科、免疫学、胃肠病学和风湿病学中的治疗适应症以及相关禁忌症。特别关注抗TNF-α治疗的历史背景，始于1998年美国食品药品监督管理局（FDA）批准，以及2002年随后在皮肤科的应用。
Zotero 插件